JP2023537676A5 - - Google Patents
Info
- Publication number
- JP2023537676A5 JP2023537676A5 JP2023503434A JP2023503434A JP2023537676A5 JP 2023537676 A5 JP2023537676 A5 JP 2023537676A5 JP 2023503434 A JP2023503434 A JP 2023503434A JP 2023503434 A JP2023503434 A JP 2023503434A JP 2023537676 A5 JP2023537676 A5 JP 2023537676A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- cancer
- subject
- agent according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063058146P | 2020-07-29 | 2020-07-29 | |
| US63/058,146 | 2020-07-29 | ||
| PCT/US2021/043395 WO2022026510A1 (en) | 2020-07-29 | 2021-07-28 | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537676A JP2023537676A (ja) | 2023-09-05 |
| JP2023537676A5 true JP2023537676A5 (enExample) | 2024-08-06 |
Family
ID=77666547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503434A Pending JP2023537676A (ja) | 2020-07-29 | 2021-07-28 | トラスツズマブ、タキサン及びｖｅｇｆｒ－２アンタゴニストと組み合わせたツカチニブによりｈｅｒ２陽性癌を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230270745A1 (enExample) |
| EP (1) | EP4188384A1 (enExample) |
| JP (1) | JP2023537676A (enExample) |
| KR (1) | KR20230047359A (enExample) |
| CN (1) | CN116723858A (enExample) |
| AU (1) | AU2021315520A1 (enExample) |
| CA (1) | CA3189333A1 (enExample) |
| IL (1) | IL300052A (enExample) |
| MX (1) | MX2023001233A (enExample) |
| WO (1) | WO2022026510A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| WO2024089702A1 (en) * | 2022-10-28 | 2024-05-02 | Natco Pharma Limited | An improved process for the preparation of tucatinib and its salt & polymorphs thereof |
| KR20250139608A (ko) * | 2024-03-15 | 2025-09-23 | 충북대학교 산학협력단 | 오시머티닙, 에토포사이드 및 도세탁셀이 봉입된 폴리비닐 카프로락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그래프트 공중합체 마이셀 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU2012323890A1 (en) | 2011-10-14 | 2014-05-29 | Array Biopharma Inc. | Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them |
| WO2013056108A2 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Solid dispersion |
| MX2014013763A (es) * | 2012-05-11 | 2015-02-20 | Merrimack Pharmaceuticals Inc | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. |
| BR112019022280A2 (pt) * | 2017-04-28 | 2020-05-19 | Seattle Genetics Inc | tratamento de cânceres de her2 positivo |
-
2021
- 2021-07-28 US US18/017,905 patent/US20230270745A1/en active Pending
- 2021-07-28 JP JP2023503434A patent/JP2023537676A/ja active Pending
- 2021-07-28 CA CA3189333A patent/CA3189333A1/en active Pending
- 2021-07-28 WO PCT/US2021/043395 patent/WO2022026510A1/en not_active Ceased
- 2021-07-28 CN CN202180060011.7A patent/CN116723858A/zh active Pending
- 2021-07-28 AU AU2021315520A patent/AU2021315520A1/en not_active Abandoned
- 2021-07-28 MX MX2023001233A patent/MX2023001233A/es unknown
- 2021-07-28 EP EP21766544.7A patent/EP4188384A1/en active Pending
- 2021-07-28 KR KR1020237001749A patent/KR20230047359A/ko active Pending
- 2021-07-28 IL IL300052A patent/IL300052A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537676A5 (enExample) | ||
| JP2023502929A5 (enExample) | ||
| JP2023101813A (ja) | 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ | |
| JP2022095908A5 (enExample) | ||
| JP2024178243A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| TWI818120B (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| Burris III | Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer | |
| JP2023507190A5 (enExample) | ||
| Li et al. | HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives | |
| JP2021515017A5 (enExample) | ||
| JPH07316074A (ja) | 腫瘍および炎症性疾患を選択的に治療するために用いられる、壊死を引き起こす物質と、壊死により活性化される物質との組み合わせ | |
| JP2021501776A5 (enExample) | ||
| JP2010150286A (ja) | 腫瘍の治療のための免疫療法的併用 | |
| JP2023533937A5 (enExample) | ||
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| JP2021528496A5 (enExample) | ||
| JP2023539589A5 (enExample) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023527794A5 (enExample) | ||
| JP2022523045A5 (enExample) | ||
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| Sachdev et al. | Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer | |
| CN112121048A (zh) | 用于联合治疗食管癌的喹啉类化合物 |